Synonyms: MMV687273 | SQ 109 | SQ109
Compound class:
Synthetic organic
Comment: SQ-109 is a [1,2]-diamine-based ethambutol analogue included in the Medicines for Malaria Pandemic Response Box (MMV PRB). Functionally, it inhibits Mycobacterial membrane protein large 3 (MmpL3) and has advanced to clinical evaluation for the treatment of tuberculosis [5].
The compound also has antimalarial activity. The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. ![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Guide to Malaria Pharmacology Comments |
Using a parallel screening approach, chemotypes from the MMV PRB were assessed for stage-specific activity across all lifecycle stages of the Plasmodium parasite [4]. This screen identified SQ-109 as a selective inhibitor of late-stage P. falciparum gametocytes with potent transmission-targeted activity. Potential Target/Mechanism Of Action: As the precise mechanism of action of SQ-109 is not yet known, we do not have a molecular target for this compound. Further information about possible mechanistic insights is provided under the Clinical data tab. |